favipiravir in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
0.69 [0.28 ; 1.68 ] FACCT Trial, 2021 1 0% 254 NA not evaluable deathsdetailed results Dabbous HM, 2020 0.51 [0.02; 15.41]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74]
NCT04542694, 2020 1.00 [0.02; 50.90]
Udwadia, 2020 0.50 [0.02; 15.03]
0.91 [0.45 ; 1.86 ] Dabbous HM, 2020, FACCT Trial, 2021, Lou (FAVIPIRAVIR), 2020, NCT04542694, 2020, Udwadia, 2020 5 0% 722 moderate not evaluable clinical improvementdetailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Udwadia, 2020 1.75 [1.10; 2.79]
1.65 [1.28 ; 2.13 ] AVIFAVIR, 2020, Lou (FAVIPIRAVIR), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Udwadia, 2020 5 0% 597 moderate not evaluable clinical improvement (14-day)detailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
1.26 [1.04 ; 1.53 ] AVIFAVIR, 2020, Lou (FAVIPIRAVIR), 2020, Ruzhentsova T, 2020 3 0% 247 moderate not evaluable clinical improvement (28-day)detailed results Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Udwadia, 2020 1.75 [1.10; 2.79]
1.32 [0.86 ; 2.03 ] Ruzhentsova T, 2020, Udwadia, 2020 2 70% 318 moderate not evaluable clinical improvement (7-day)detailed results NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
1.62 [1.15 ; 2.28 ] NCT04542694, 2020, Ruzhentsova T, 2020 2 0% 368 moderate not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Shinkai, 2021 1.40 [0.91; 2.15]
Udwadia, 2020 1.75 [1.10; 2.79]
1.33 [0.93 ; 1.90 ] FACCT Trial, 2021, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 4 71% 728 moderate not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
Udwadia, 2020 1.41 [0.97; 2.03]
1.10 [0.69 ; 1.75 ] FACCT Trial, 2021, Udwadia, 2020 2 72% 404 moderate not evaluable mechanical ventilationdetailed results Udwadia, 2020 0.06 [0.01; 0.83]
0.06 [0.01 ; 0.83 ] Udwadia, 2020 1 0% 14 NA not evaluable mechanical ventilation (time to event analysis only)detailed results Udwadia, 2020 0.06 [0.01; 0.83]
0.06 [0.01 ; 0.83 ] Udwadia, 2020 1 0% 14 NA not evaluable viral clearance detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Dabbous HM, 2020 1.33 [0.60; 2.93]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
NCT04542694, 2020 13.03 [2.96; 57.24]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Udwadia, 2020 1.37 [0.94; 1.98]
1.75 [1.07 ; 2.87 ] AVIFAVIR, 2020, Dabbous HM, 2020, Lou (FAVIPIRAVIR), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Udwadia, 2020 6 63% 696 moderate not evaluable viral clearance (time to event analysis only)detailed results Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Udwadia, 2020 1.37 [0.94; 1.98]
1.32 [1.03 ; 1.69 ] Ruzhentsova T, 2020, Udwadia, 2020 2 0% 318 moderate not evaluable viral clearance by day 14detailed results AVIFAVIR, 2020 3.08 [0.62; 15.39]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
1.12 [0.48 ; 2.63 ] AVIFAVIR, 2020, Lou (FAVIPIRAVIR), 2020, Ruzhentsova T, 2020 3 32% 247 moderate not evaluable viral clearance by day 7detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Dabbous HM, 2020 1.33 [0.60; 2.93]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
1.44 [0.78 ; 2.65 ] AVIFAVIR, 2020, Dabbous HM, 2020, Ruzhentsova T, 2020 3 61% 327 moderate not evaluable ICU admissiondetailed results FACCT Trial, 2021 1.42 [0.79; 2.55]
Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89]
1.48 [0.83 ; 2.64 ] FACCT Trial, 2021, Lou (FAVIPIRAVIR), 2020 2 0% 273 moderate not evaluable serious adverse eventsdetailed results NCT04542694, 2020 6.15 [0.30; 124.49]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Shinkai, 2021 2.80 [0.14; 56.95]
Udwadia, 2020 1.03 [0.02; 52.48]
2.73 [0.55 ; 13.60 ] NCT04542694, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 4 0% 667 moderate not evaluable adverse eventsdetailed results NCT04542694, 2020 1.00 [0.54; 1.85]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Shinkai, 2021 19.54 [7.77; 49.11]
Udwadia, 2020 6.36 [2.43; 16.65]
3.78 [1.07 ; 13.38 ] NCT04542694, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 4 91% 667 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 15:43 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 513
- roots T: 290
